Cornell study points to broader role for cystinosin in cystinosis
Bottom line
Cornell University College of Veterinary Medicine researchers report that cystinosin, the protein mutated in cystinosis, may do more than clear cystine from lysosomes. In a new Molecular Biology of the Cell study, Richa Sardana’s team used yeast models, proteomics, metabolomics, and electrophysiology to show that the yeast homolog of cystinosin functions in the early secretory pathway, where it appears to help maintain cellular redox balance rather than transport cystine. The group also found that a human extra-lysosomal cystinosin isoform, CTNS-LKG, could functionally replace the yeast protein, suggesting that this noncanonical role may be evolutionarily conserved. Cornell said the findings could help explain why reducing cystine buildup alone doesn’t fully prevent major complications of cystinosis. (vet.cornell.edu)
Why it matters: For veterinary and comparative biomedical researchers, the study adds to a growing body of evidence that cystinosin biology extends beyond lysosomal cystine transport. That matters because current cystine-lowering therapy can slow disease progression but doesn’t prevent key manifestations such as renal Fanconi syndrome, and other recent work has also pointed to cystinosin-dependent trafficking functions in kidney proximal tubule cells. While cystinosis is a human rare disease, the work underscores how veterinary school-based cell biology programs can surface broader mechanisms with translational relevance across nephrology, genetics, and membrane transport research. (link.springer.com)
What to watch: Whether follow-up studies can show that targeting cystinosin’s extra-lysosomal or redox-related functions improves outcomes beyond cystine depletion alone, especially as gene and cell therapies for cystinosis continue to advance. (vet.cornell.edu)
Key facts
- Study type
- Cornell-led basic science study
- Journal
- Molecular Biology of the Cell
- Protein studied
- Cystinosin
- Disease context
- Cystinosis
- Model system
- Yeast homolog Ers1
- Main finding
- The yeast homolog functions in the early secretory pathway and appears to support redox balance, not cystine transport
- Human isoform
- CTNS-LKG
- Translational finding
- CTNS-LKG could functionally replace the yeast protein
- Implication
- Reducing cystine buildup alone may not fully prevent major complications of cystinosis
A new Cornell-led study is challenging the standard view of cystinosin, the protein defective in cystinosis. In findings highlighted by Cornell University College of Veterinary Medicine and published in Molecular Biology of the Cell, Richa Sardana’s lab reports that cystinosin’s yeast homolog works in the early secretory pathway and appears to support redox homeostasis, pointing to functions beyond the protein’s established role in cystine export from lysosomes. (vet.cornell.edu)
That question has been building for years. Cystinosis is caused by pathogenic variants in CTNS, which encodes cystinosin, and standard treatment strategies have focused on lowering lysosomal cystine. But clinicians and researchers have long recognized that controlling cystine accumulation does not fully prevent major disease complications. Recent literature has increasingly described additional cystinosin-linked pathways, including autophagy, inflammation, transcriptional regulation, and proximal tubule transport defects, suggesting that the disease mechanism is broader than storage alone. (vet.cornell.edu)
In the new work, the Cornell team studied Ers1, the yeast homolog of cystinosin. According to the lab summary and the bioRxiv version of the paper, Ers1 localized mainly to the early Golgi rather than the vacuole, the yeast equivalent of the lysosome. The researchers reported that deleting ERS1 did not produce cystine accumulation in yeast and that they could not detect cystine-dependent transport in electrophysiology experiments. Instead, genetic and metabolomic data linked Ers1 to redox regulation in the early secretory pathway. (sardanalab.vet.cornell.edu)
One of the more notable translational details is the role of CTNS-LKG, an alternatively spliced human cystinosin isoform with extra-lysosomal localization. The Cornell group reported that CTNS-LKG could functionally replace Ers1 in yeast, which they interpret as evidence for a conserved noncanonical function. The bioRxiv manuscript also notes that CTNS-LKG is expressed in tissues tied to important cystinosis manifestations, including renal proximal tubular cells, pancreatic islets, testicular Leydig cells, and pigment-producing skin cells, although its precise role in disease remains unclear. (sardanalab.vet.cornell.edu)
The study lands in the context of other 2026 research expanding the cystinosin story. An EMBO Reports paper found that cystinosin regulates NHE3 trafficking and function in kidney proximal tubular cells, offering a mechanistic explanation for early renal Fanconi syndrome in cystinosis and reinforcing the idea that cystinosin has disease-relevant functions that cystine depletion alone does not fix. That convergence across model systems strengthens the broader argument that future therapies may need to restore or mimic multiple cystinosin functions, not just reduce substrate burden. (link.springer.com)
Expert reaction in the narrow sense was limited in publicly available coverage, but Sardana said in Cornell’s release that the findings “could have a fundamental impact” on therapeutic strategy, with the possibility of combining approaches that address both cystine buildup and the protein’s other cellular roles. That view is directionally consistent with the current treatment landscape: a 2026 New England Journal of Medicine report described early clinical results for hematopoietic stem-cell gene therapy for cystinosis, reflecting continued momentum toward therapies that restore functional CTNS rather than only manage downstream metabolite accumulation. (vet.cornell.edu)
Why it matters: For veterinary professionals, especially those following comparative medicine and translational research, this is a reminder that veterinary colleges are contributing to mechanism-first discoveries with implications well beyond animal health. The immediate clinical relevance to companion animal practice may be limited because cystinosis is a rare human genetic disease, but the scientific relevance is broader: membrane transporter biology, redox control, intracellular trafficking, and kidney disease mechanisms are all active areas with crossover value for veterinary nephrology and inherited disease research. It also illustrates how yeast and other model systems can reveal conserved biology that later informs drug development. (vet.cornell.edu)
What to watch: The next step is whether these extra-lysosomal functions can be validated directly in mammalian and patient-derived systems, and whether they can be therapeutically targeted alongside cystine-lowering or gene-based approaches. If they can, this line of work could reshape how the field defines successful treatment in cystinosis over the next several years. (vet.cornell.edu)